- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05792670
Can High Ventilation Provide Higher Success Rates in Retrograde Intrarenal Surgery?
March 30, 2023 updated by: Cagri DOGAN, Namik Kemal University
Can High Ventilation Mode Achieve Higher Success Rates in Retrograde Intrarenal Surgery? Single-Blind Randomized, Prospective, Single-Center Study
RIRS (Retrograde Intrarenal Surgery) has been accepted as a first-line treatment option for urinary stones smaller than 2 cm and is generally performed under general anesthesia to manipulate respirator-related renal mobility.
Many surgeons prefer general anesthesia during RIRS to minimize respiration-related renal mobility.
Standard mechanical ventilation settings were still inadequate to limit renal mobility and the surgeons tried to find the most effective ventilation mode to minimize renal mobility.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
A standard general anesthesia protocol is given to all patients by the same anesthesiologist.
A Drager Primus (Germany) mechanic ventilator (MV) is preferred for general anesthesia.
The MV will determine the tidal volume and respiration frequency according to the patient's age and weight with end-tidal CO2 levels of 30-35 mmHg.
Standard ventilation mode is 8-10 mL/kg tidal volume and 10-15 respirations/min.
During HV mode, the tidal volume will decrease to 6-8 mL/kg and the frequency will increase to 15-18 respirations/min.
No changes are made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.
The ventilation mode of the mechanic ventilator (SV or HV) is determined via randomization software before the surgery.
According to randomization, the anesthesiologist is informed about the ventilation mode but the surgeons are absolutely blind.
A high ventilation mode is formed by increasing the respiration frequency and decreasing the study's tidal volume.
The aim of the study was to evaluate the effect of this mode on the efficacy and safety of RIRS.
Study Type
Interventional
Enrollment (Anticipated)
140
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cagri Dogan, Asst.Prof.
- Phone Number: +9005558908805
- Email: drcagridogan@gmail.comn
Study Contact Backup
- Name: Cenk Murat Yazıcı, Prof.Dr
- Phone Number: +905068552687
- Email: drcenkyazici@yahoo.com
Study Locations
-
-
Please Select:
-
Tekirdag, Please Select:, Turkey, 59100
- Recruiting
- Cagri Dogan
-
Contact:
- Cagri Dogan, Asst.Prof.
- Phone Number: +9005558908805
- Email: drcagridogan@gmail.com
-
Contact:
- Cenk Murat YAzıcı, Prof.Dr.
- Phone Number: +905068552687
- Email: drcenkyazici@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 86 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients who underwent RIRS with kidney stones older than18 y.o
Exclusion Criteria:
Patients younger than 18 years old Patients with a known respiratory disease Patients with a renal anomaly Proximal ureteral stones, or stones with multiple locations The patients who underwent previous ipsilateral percutaneous nephrolithotomy and/or open renal surgery were excluded from the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard Ventilatation Mode
SV mode is defined according to the mechanical ventilator parameters (patients' age and weight) Standard ventilation mode is defined as 8-10 mL/kg tidal volume and 10-15 respirations/min.
No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters
|
The tidal volume and respiration frequency were determined by the MV according to patient's age and weight with end-tidal CO2 levels of 30-35 mmHg.
Standard ventilation mode was defined as 8-10 mL/kg tidal volume and 10-15 respirations/min.
During HV mode, the tidal volume was decreased to 6-8 mL/kg and the frequency was increased to 15-18 respirations/min.
No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.
|
|
Active Comparator: High Ventilatation Mode
Hv mode is defined as the tidal volume decreased to 6-8 mL/kg and the frequency is increased to 15-18 respirations/min.
No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters
|
The tidal volume and respiration frequency were determined by the MV according to patient's age and weight with end-tidal CO2 levels of 30-35 mmHg.
Standard ventilation mode was defined as 8-10 mL/kg tidal volume and 10-15 respirations/min.
During HV mode, the tidal volume was decreased to 6-8 mL/kg and the frequency was increased to 15-18 respirations/min.
No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
perioperatively data of RIRS procedure according to different ventilatation modes
Time Frame: During the surgical procedure
|
perioperatively data including e.g.
operation time
|
During the surgical procedure
|
|
Complicatation of perioperatively during RIRS
Time Frame: During the surgical procedure
|
The presence of perioperative bleeding, perioperative bleeding, ureteral perforation, bladder perforation, ureteral avulsion
|
During the surgical procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post operative success rates
Time Frame: At the postoperative first month of surgery
|
The stone free status and residue stone volume according to CT
|
At the postoperative first month of surgery
|
|
Post operative complication
Time Frame: From postoperative first day to postoperative 1. month
|
Postoperative complication status including urosepsis, fever, renal colic, flank pain, bleeding and stent migration etc.
|
From postoperative first day to postoperative 1. month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Cagri Dogan, Asst.Prof., Tekirdag Namik Kemal University
- Principal Investigator: Cenk Murat Yazici, Prof.Dr., Tekirdag Namik Kemal University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2023
Primary Completion (Actual)
February 25, 2023
Study Completion (Anticipated)
April 30, 2023
Study Registration Dates
First Submitted
March 1, 2023
First Submitted That Met QC Criteria
March 30, 2023
First Posted (Actual)
March 31, 2023
Study Record Updates
Last Update Posted (Actual)
March 31, 2023
Last Update Submitted That Met QC Criteria
March 30, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 2022.179.10.03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.